HOXC6 Drives a Therapeutically Targetable Pancreatic Cancer Growth and Metastasis Pathway by Regulating MSK1 and PPP2R2B
Investigators demonstrated that the transcription factor, homeobox C6 (HOXC6), was overexpressed in most PDACs, and its inhibition blocked PDAC tumor growth and metastasis.
[FDA] The FDA has received reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
[Nature Biomedical Engineering] Investigators showed that replacement of the extracellular domains of heterodimeric cytokine receptors in T cells with two leucine zipper motifs provided optimal Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling.
[blood] The authors presented the clinicogenomic characterization of a CARTITUDE-4 patient who developed a CAR+ T cell lymphoma post cilta-cel. Diagnostic and staging workup included biopsy analyses and FDG-PET scan.